Studies have shown that EVs can deliver miR-199a to target the mTOR pathway, inhibiting mTOR activation and subsequent phosphorylation of 4EBP1 and 70S6K in hepatocellular carcinoma (HCC) cells, thus restoring doxorubicin sensitivity in HCC cells[189]. This evidence concerns the gene EIF4EBP1 and hepatocellular carcinoma.